Trial Profile
An Open Label, Randomized, Parallel Arm Clinical Trial of Two Regimens to Assess the Safety and Efficacy for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in Sudan
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Amphotericin B liposomal (Primary) ; Miltefosine (Primary) ; Paromomycin (Primary)
- Indications Cutaneous leishmaniasis
- Focus Adverse reactions; Therapeutic Use
- 20 Sep 2018 New trial record
- 12 Sep 2018 According to Drugs for Neglected Diseases Initiative Foundation media release, New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier